Report Date: Friday, July 31, 2026 (before market open) | Event: Q2 2026 Earnings Call
CHD shares closed at $97.70 on July 30, having traded in a $81–$106 range over the trailing year and gained roughly 18% year-to-date coming into the print. The stock carries a "Moderate Buy" / "Buy" consensus among the ~17-20 analysts covering it, with average price targets clustered around $102–$112, implying modest upside from current levels. Consensus estimates for Q2 sit right in line with — or fractionally above — management's own guidance, which is an important framing point: this is a print where "meeting guidance" is close to the bar, not clearing a beat-friendly one.
Unlike many companies, CHD gave unusually specific quarter-ahead guidance on its Q1 call, which sets the bar for tomorrow:
We expect organic sales growth of approximately 3% in the second quarter and we expect a reported sales decline of approximately 1% due entirely to the strategic portfolio actions in 2025. Also in the second quarter, we expect gross margin expansion of approximately 50 basis points, reflecting pressure from transportation costs prior to mitigation efforts taking effect later in the year. Management also flagged that the higher marketing and SG&A, which includes Touchland amortization, will more than offset the higher gross margin resulting in an expected Adjusted EPS of $0.88 per share for the quarter. CFO Lee McChesney reiterated on the call that we continue to expect flattish EPS growth in the first half of 2026, with the growth algorithm weighted to H2.
Watch for: whether reported sales, organic growth, and gross margin land at/above this guide (as they did handily in Q1) or whether the incremental Middle East/commodity cost pressure flagged in Q1 bites harder than expected.
Q1 was a "high-quality beat." Net sales increased 0.2%, ahead of our expectation for a decline and organic sales grew 5%, well above our 3% outlook. This growth was driven by volume. Adjusted gross margin expanded 130 basis points to 46.4% and adjusted EPS was $0.95, up 4.4% year-over-year and above our $0.92 outlook.
Key drivers investors should track for continuation into Q2: - Distribution gains: Management noted Church & Dwight was #1 across all of CPG on total distribution points gained year-over-year, with CEO Rick Dierker later quantifying that on a trailing basis distribution gains were running about double what most of the CPG peers are getting — a tailwind that should still be building into Q2. - Category growth firming: Categories tracked closer to 3% in Q1 versus an initial ~2% full-year assumption, and Dierker noted category trends were better than we expected... I am more enthusiastic than I was 90 days ago. - One-time tailwind fading: Roughly 2 points of Q1's 5% organic growth came from a prior-year retail inventory drawdown comp so we grew our business around 3% and we had that 2% help. That's 5% organic. This helps explain why Q2 organic guidance (~3%) is meaningfully below Q1's 5% actual — it is not a deceleration in underlying demand, just the lapping of an easy comp. - Brand highlights: THERABREATH (share up 3.5 pts to 24.1% in mouthwash), HERO (share leader, 2x nearest competitor), ARM & HAMMER laundry (record share) and cat litter (+6.8% consumption, share to 24.6%) all posted strong quarters, while OXICLEAN and Touchland were softer spots — OXICLEAN due to lapping a club distribution loss, and Touchland due to a tough compare against a strong Q4 holiday multipack sell-in.
On the Q1 call, management flagged a fresh headwind: we currently are estimating $25 million to $30 million of incremental inflation pressure tied to the Middle East conflict, based on an oil assumption of $95 to $100 per barrel. Notably, geopolitical conditions have stayed volatile through July — Brent crude spiked into the high-$80s/barrel amid attacks around the Strait of Hormuz — so this remains a live swing factor for the gross margin bridge and for whether management's productivity-first mitigation plan (no plans to raise prices at this stage) continues to hold. Dierker was explicit that pricing is the last resort: The first stop on the train is productivity. The second stop on the train is RGM on promotions... The third stop on the train would be pricing. Investors should listen for any change in tone here, and whether the $25–30M full-year estimate has grown.
Full-year guide is for ~100 bps of gross margin expansion, but Q2 specifically was only guided to ~50 bps, given transportation-cost pressure ahead of mitigation actions that take hold later in the year reflecting pressure from transportation costs prior to mitigation efforts taking effect later in the year. A miss here, or commentary suggesting H2 mitigation is running behind schedule, would be a read-through risk to the full-year 5–8% adjusted EPS growth target.
SG&A is elevated in H1 largely due to Touchland's amortization and cost structure: SG&A in the first half of the year is primarily growing versus last year due to the inclusion of Touchland's SG&A and amortization expense. Consumption trends for Touchland slowed in Q1 versus a strong prior-year holiday base, though management maintains confidence in double-digit full-year growth as advertising and brand collaborations ramp in H2: Overall, we believe that we still are going to have double-digit growth for Touchland for the full year... A lot of our activations with either collaborations or just partnerships are happening in the back half. Any update on Touchland trajectory will be closely watched.
Management has staked a lot on 2026 new-product launches — THERABREATH toothpaste, ARM & HAMMER Baking Soda Fresh (10x baking soda), HERO Mighty Shield and new facial cleansers, ARM & HAMMER Dual Defense litter, and Trojan G.O.A.T. New launches are expected to drive half of full-year organic growth, so early read-throughs on shelf resets, ratings, and retailer reorders matter.
CHD ended Q1 with $503.4 million of cash and continues to target ~$1.15 billion of full-year operating cash flow. Management reiterated an active M&A posture skewed toward "fast-moving consumable products" and international expansion, with Dierker noting the team is hard at work... it's just not in the U.S., it's also internationally. Any acquisition commentary or updated criteria would be notable, especially as the VMS TSA with the divested vitamin business winds down and frees up organizational bandwidth.
Watch for updated category growth commentary — Q1 categories ran ~3%, better than the ~2% initially assumed for the year. Persistent macro pressure (inflation, borrowing costs, potential gas-price pass-through from the Middle East conflict) could pressure discretionary categories, though management has argued CHD's value/premium balance (e.g., ARM & HAMMER as a value laundry option) helps it in a stretched-consumer environment.
| Metric | FY2026 Guidance |
|---|---|
| Organic sales growth | 3% – 4% |
| Reported net sales | -1.5% to -0.5% (portfolio actions) |
| Gross margin expansion | ~100 bps |
| Marketing % of sales | ~11% |
| Adjusted EPS growth | 5% – 8% (~$3.71–$3.81) |
| Reported EPS growth | 18% – 22% |
| Cash from operations | ~$1.15 billion |
| Capex | ~$130 million (~2% of sales) |
| Tax rate | ~21.5% |
Management's framing: While the situation in the Middle East remains fluid and is creating some incremental volume and inflationary pressure on commodities and transportation, we believe we can offset this transitory pressure and maintain our outlook for 2026. Confirmation (or walking back) of this stance is arguably the single most important message investors will listen for tomorrow.
CHD heads into Q2 earnings with credibility built up from a clean Q1 beat-and-reiterate quarter, strong innovation/distribution momentum, and share gains across its largest categories. But the setup is more delicate than it looks: guidance already calls for flattish H1 EPS growth, a step-down in organic growth (from 5% in Q1 to a guided ~3% in Q2) as easy comps roll off, and only ~50 bps of gross margin expansion as new Middle East-conflict-driven commodity and transportation costs work against productivity gains. The key swing factors for tomorrow are (1) whether Q2 results land in line with the company's own precise guidance ($0.88 EPS, ~3% organic, ~1% reported decline, ~50bps gross margin), (2) any update on the size and duration of Middle East-related cost pressure given the continued volatility in oil markets, and (3) commentary on Touchland's trajectory and H2 margin mitigation efforts that underpin the full-year 5–8% adjusted EPS growth target.